Sairy Hernandez - Med Affairs, Genentech Inc

基本信息

浏览量：2

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 33 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Racial/ethnic Disparities in the Effectiveness of Atezolizumab Plus Bevacizumab (A+B) Vs. Tyrosine Kinase Inhibitors (tkis) among Veterans with Unresectable Hepatocellular Carcinoma (Uhcc)

David Edward Kaplan,Amie Tan,Cheryl Xiang,Fan Mu,Sairy Hernandez,Sarika Ogale,Manasvi Sundar,Yilu Lin,Lizheng Shi,Amit G. Singal

JOURNAL OF CLINICAL ONCOLOGYno. 3_SUPPL (2024): 448-448

引用0浏览0引用

Comparing First-Line (1L) Atezolizumab Plus Bevacizumab (A+B) to Lenvatinib (L) or Sorafenib (S) in Patients with Unresectable Hepatocellular Carcinoma (uhcc): Findings from the National Veteran Health Administration (VHA) Database

David Edward Kaplan,Amie Tan,Cheryl Xiang, Fan Mu,Sarika Ogale,Sairy Hernandez, Jiayang Li, Yilu Lin, Lizheng Shi, Amit G. Singal

JOURNAL OF CLINICAL ONCOLOGYno. 3_SUPPL (2024): 446-446

引用0浏览0引用

Prognostic Significance of Real-World (RW) Recurrence Patterns after Resection or Ablation of Early-Stage Hepatocellular Carcinoma (HCC): Insights from the US Medicare Population

Shishir K. Maithel, Rongrong Wang,Joanna Harton,Adam C. Yopp,Shimul Shah,Flavio G. Rocha,Sairy Hernandez, Spencer Cheng,Sarika Ogale,Amie Tan

Journal of Clinical Oncologyno. 16_suppl (2024): e16241-e16241

引用0浏览0引用

Efficacy and Safety of Atezolizumab Plus Bevacizumab Vs Sorafenib in Hepatocellular Carcinoma with Main Trunk And/or Contralateral Portal Vein Invasion in IMbrave150

Richard S Finn,Peter R Galle,Michel Ducreux,Ann-Lii Cheng,Norelle Reilly,Alan Nicholas,Sairy Hernandez, Ning Ma,Philippe Merle,Riad Salem,Daneng Li,Valeriy Breder

Liver cancerno. 6 (2024): 655-668

引用0浏览0WOS引用

Clinical Outcomes and Histologic Findings of Patients with Hepatocellular Carcinoma with Durable Partial Response or Durable Stable Disease after Receiving Atezolizumab Plus Bevacizumab

Journal of clinical oncology official journal of the American Society of Clinical Oncologyno. 34 (2024): 4060-4070

引用0浏览0WOS引用

Overall Survival in Real-World Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Versus Sorafenib or Lenvatinib As First-Line Therapy: Findings from the National Veterans Health Administration Database

David E. Kaplan,Ruoding Tan,Cheryl Xiang,Fan Mu,Sairy Hernandez,Sarika Ogale, Jiayang Li,Yilu Lin,Lizheng Shi,Amit G. Singal

CANCERSno. 20 (2024)

引用0浏览0WOS引用

Race/ethnicity and Socioeconomic Position in Emergency Department Utilization in Patients with Hepatocellular Carcinoma

Daniel Lin,Ruoding Tan,Christie Teigland,Sairy Hernandez,Seung Kim,Karl M. Kilgore

Future Oncologypp.1-13, (2024)

引用0浏览0WOS引用

Atezolizumab Plus Bevacizumab (A+B) in Patients with Unresectable Hepatocellular Carcinoma (uhcc): Real-world Experience from a US Community Oncology Network

David Cosgrove,Amie Tan, Andrew Osterland,Sairy Hernandez,Sarika Ogale,Sami Mahrus, John Murphy, Thomas W. Wilson,Gregory A. Patton,Arturo Loaiza-Bonilla,Amit G. Singal

JOURNAL OF CLINICAL ONCOLOGYno. 3_SUPPL (2024): 447-447

引用0浏览0引用

IMbrave050: Efficacy, Safety and Patient-Reported Outcomes (pros) for Adjuvant Atezolizumab (atezo) + Bevacizumab (bev) Vs Active Surveillance in Hepatocellular Carcinoma (HCC) Patients at High Risk of Disease Recurrence after Resection or Ablation

Ahmed Kaseb,Minshan Chen,Pierce Chow,Masatoshi Kudo,Han Chu Lee,Adam Yopp,Lars Becker,Sairy Hernandez,Bruno Kovic,Qinshu Lian,Ning Ma,Chun Wu,Shukui Qin,Ann-Lii Cheng

Journal of Clinical Oncology（2023）

引用0浏览0引用

Supplementary Table from Alpha-Fetoprotein As a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma

Andrew X. Zhu, Farshid Dayyani,Chia-Jui Yen,Zhenggang Ren,Yuxian Bai,Zhiqiang Meng,Hongming Pan, Paul Dillon,Shivani K. Mhatre,Vincent E. Gaillard,Sairy Hernandez, Robin Kate Kelley,Bruno Sangro

openalex（2023）

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn